The stock of Axovant Sciences Ltd (NYSE:AXON) is a huge mover today! About 113,232 shares traded hands. Axovant Sciences Ltd (NYSE:AXON) has risen 7.67% since March 7, 2016 and is uptrending. It has outperformed by 0.08% the S&P500.
The move comes after 8 months positive chart setup for the $1.37B company. It was reported on Oct, 10 by Barchart.com. We have $20.19 PT which if reached, will make NYSE:AXON worth $630.20 million more.
Analysts await Axovant Sciences Ltd (NYSE:AXON) to report earnings on November, 7. They expect $-0.39 earnings per share, down 225.00% or $0.27 from last year’s $-0.12 per share. After $-0.38 actual earnings per share reported by Axovant Sciences Ltd for the previous quarter, Wall Street now forecasts 2.63% negative EPS growth.
Axovant Sciences Ltd (NYSE:AXON) Ratings Coverage
Out of 4 analysts covering Axovant Sciences (NYSE:AXON), 3 rate it a “Buy”, 1 “Sell”, while 0 “Hold”. This means 75% are positive. Axovant Sciences has been the topic of 4 analyst reports since September 25, 2015 according to StockzIntelligence Inc. The firm has “Sell” rating by Chardan Capital Markets given on Friday, September 25. Leerink Swann initiated Axovant Sciences Ltd (NYSE:AXON) on Tuesday, June 7 with “Outperform” rating. The stock of Axovant Sciences Ltd (NYSE:AXON) earned “Overweight” rating by Piper Jaffray on Thursday, October 22. H.C. Wainwright initiated Axovant Sciences Ltd (NYSE:AXON) on Friday, January 8 with “Buy” rating.
According to Zacks Investment Research, “Axovant Sciences Ltd. is a biopharmaceutical company which focuses on the acquisition, development and commercialization of therapeutics for the treatment of neurodegenerative disorders. Its product candidate includes RVT-101 which is in different clinical trial for the treatment of Alzheimer’s disease and other forms of dementia. Axovant Sciences Ltd. is based in Hamilton, Bermuda.”
More notable recent Axovant Sciences Ltd (NYSE:AXON) news were published by: Investorplace.com which released: “Why Axovant Sciences Ltd (AXON), Jabil Circuit, Inc. (JBL) and Virgin America …” on September 22, 2016, also Quotes.Wsj.com with their article: “News Axovant Sciences Ltd.AXON” published on June 05, 2015, Prnewswire.com published: “Axovant Sciences Ltd. Announces Pricing of Initial Public Offering” on June 11, 2015. More interesting news about Axovant Sciences Ltd (NYSE:AXON) were released by: Prnewswire.com and their article: “Axovant Sciences Ltd. Announces Completion of Initial Public Offering and Full …” published on June 16, 2015 as well as Fool.com‘s news article titled: “Why Axovant Sciences Skyrocketed 56% in November” with publication date: December 03, 2015.
AXON Company Profile
Axovant Sciences Ltd., formerly Roivant Neurosciences Ltd., incorporated on October 31, 2014, is a clinical-stage biopharmaceutical firm focused on acquiring, developing and commercializing therapeutics for the treatment of dementia. The Firm focuses on developing a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.